Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 08, 2023

BUY
$314.42 - $351.91 $2,515 - $2,815
8 Added 17.78%
53 $18,000
Q1 2023

Apr 13, 2023

SELL
$283.23 - $323.1 $62,310 - $71,082
-220 Reduced 83.02%
45 $14,000
Q4 2022

Jan 13, 2023

BUY
$285.76 - $321.48 $59,152 - $66,546
207 Added 356.9%
265 $0
Q4 2021

Jan 31, 2022

SELL
$177.01 - $223.45 $2,655 - $3,351
-15 Reduced 20.55%
58 $13,000
Q3 2021

Oct 12, 2021

BUY
$181.39 - $202.99 $2,358 - $2,638
13 Added 21.67%
73 $13,000
Q2 2021

Jul 15, 2021

BUY
$187.49 - $221.1 $4,687 - $5,527
25 Added 71.43%
60 $12,000
Q1 2021

May 03, 2021

BUY
$207.02 - $241.31 $7,245 - $8,445
35 New
35 $8,000
Q3 2019

Nov 06, 2019

SELL
$166.23 - $187.09 $10,804 - $12,160
-65 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
65
65 $8,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Focused Wealth Management, Inc Portfolio

Follow Focused Wealth Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Focused Wealth Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Focused Wealth Management, Inc with notifications on news.